The group wants to improve on its own Welireg in a new phase 3 trial.
ApexOnco Front Page
Recent articles
Replimune gets a second chance, while Sarclisa could go subcutaneous.
Two new pivotal Chinese first-line trials have started in lung cancer.
New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
The company will start a phase 2/3 trial of PF-08634404 in March.
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
